Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Opinion · CompePharma View

Self-funding is the milestone small-cap pharma should be chasing this earnings season

Delcath turns growth into profit and cash, Autolus is widening its margin, and others still lean on the balance sheet. Operating leverage is the clearest dividing line in this season's results.

17 Nov 2026 · CompePharma editorial

The quarter's quiet headline

Earnings season usually invites a ranking by growth rate. Autolus reported AUCATZYL net product revenue of $41.2 million, up 95% year over year. Tonix said TONMYA net sales rose 37% from the second quarter to approximately $15 million. Delcath's total revenue reached $35.1 million against $20.6 million a year earlier. All three are fast-growing launches, and all three deserve credit.

The more useful question is what happens after the revenue line. Here the group splits, and the split matters more than the growth rates.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.

More Opinion · CompePharma ViewAll →
Opinion · CompePharma View

Gross margin is the number that turns a launch into a business

Revenue growth was easy to find in this earnings season. The companies that pair it with unit economics, as Delcath and Autolus have begun to, are the ones that will set their own terms.

18 Nov 2026 · CompePharma editorial